公司最新总资产周转率为0.16次。最新存货周转率为1.15次。 公司股东户数为1.27万户，前十大股东持股数量为1.12亿股，占总股本比例为74.03%，前十大股东持股情况如下： 公司最新资产负债率为8.29%，较去年同期资产负债率增加0.75个百分点。 公司最新毛利率为44.52%。最新ROE为4.35%，较去年同期ROE减少0.21个百分点。 公司摊薄每股收益为0.41元。 | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l 浙江海森控股有限公司 | | 32.3 | | 2 王式跃 | | 19.5. | | 3 | 东阳泰齐投资管理合伙企业(有限合伙) | 10.8 | | 郭海燕 4 | | 3.31 | | 5 艾林 | | 3.31 | | 6 王雨濤 | | 2.51 | | 7 王冬艳 | | 1.14 | | 8 毛海海 | | 0.45 | | ਰੇ UBS AG | | 0.33 | | 10 BARCLAYS BANK PLC | | 0.29 | 2025年8月15日，海森药业(001367.SZ)发布2025年中报。 公司营业总收入为2.42亿元 ...

Group 1 - The company held its 14th meeting of the third board of directors on August 13, 2025, with all seven directors present, ensuring compliance with relevant laws and regulations [3][4]. - The board approved the 2025 semi-annual report and its summary, which accurately reflects the company's operational status and financial information for the first half of 2025 [4][6]. - The board also approved a special report on the storage and use of raised funds for the first half of 2025, confirming compliance with regulations and no misuse of funds [6][7]. Group 2 - The company proposed amendments to its Articles of Association and related rules to enhance governance structure and align with the latest legal requirements, including the adjustment of internal supervisory bodies [9][10]. - The amendments require approval from the second extraordinary general meeting of shareholders in 2025, with the management authorized to complete necessary registration and filing procedures [9][10]. - The board approved several governance system revisions, including the investment management system and the guarantee management system, which will also be submitted for shareholder approval [12][15]. Group 3 - The board passed multiple resolutions to revise various governance documents, including the independent director work system and the internal audit system, all pending shareholder approval [27][41]. - The company aims to ensure that its governance practices remain in sync with regulatory requirements and improve operational mechanisms [12][39].

Core Viewpoint - The company is advancing its strategic development by investing in a new manufacturing facility and adjusting its fundraising projects to meet market demands, with a focus on enhancing production capacity for key pharmaceutical products. Group 1: Company Overview - The company has signed an investment cooperation agreement with the Dongyang Economic Development Zone Management Committee to invest in the "Haisen Pharmaceutical New Plant Construction Project (Phase I)" with a total investment of no less than 2 billion RMB [5]. - The company has not changed its controlling shareholder or actual controller during the reporting period [4][5]. Group 2: Financial Data and Fundraising - The company raised a total of 756.16 million RMB from its initial public offering, with a net amount of 675.72 million RMB after deducting underwriting fees and other expenses [10]. - As of June 30, 2025, the company had a balance of 7.53 million RMB in unused raised funds, with 4 million RMB allocated for permanent working capital and 3.53 million RMB for the new project [21]. Group 3: Project Updates - The company has changed its fundraising project from "Annual Production of 200 Tons of Atorvastatin Calcium Technical Transformation Project" to "Annual Production of 300 Tons of A-40 (Atorvastatin Calcium) and Other Specialty Raw Material Construction Project" to better align with market trends [6]. - The construction of the R&D center and comprehensive office building has been completed, with equipment installation ongoing, leading to a delay in the investment schedule [7]. Group 4: Profit Distribution and Capital Changes - The company approved a profit distribution plan for 2024, which includes a cash dividend of 1.70 RMB per 10 shares and a capital reserve transfer of 4.8 shares for every 10 shares held [8]. - The registered capital has increased from 102.65 million RMB to 151.93 million RMB following the implementation of the profit distribution plan [8]. Group 5: Regulatory Compliance - The company has adhered to regulations regarding the management and use of raised funds, ensuring that there are no violations in the storage, usage, and disclosure of these funds [25].

Core Insights - The company reported a revenue growth of 14.93% to 242 million yuan in the first half of 2025, with net profit attributable to shareholders increasing by 4.74% to 60.79 million yuan [1] Revenue and Profit Performance - Revenue increased by 14.93% to 242 million yuan [1] - Net profit attributable to shareholders rose by 4.74% to 60.79 million yuan [1] Product Development and Market Share - The company has focused on developing potential products, including raw materials and intermediates such as sucralfate, phenacetin, atorvastatin calcium, and PHBA, achieving high market shares [1] - Products like escitalopram oxalate, parecoxib sodium, and GABOB are expanding in sales and market share [1] Business Segment Performance - Sales of raw materials and intermediates grew by 13.94% and 29.24% year-on-year, respectively, driving overall performance [1] Market Expansion and Global Strategy - The company has optimized its market structure through global expansion, with domestic market stability and significant growth in international sales, which increased by 53.04% year-on-year [1] - The company continues to enhance its supplier qualification process and strengthen market development in the Americas and Europe, leading to a steady increase in market share [1]

证券日报网讯 8月14日晚间，海森药业发布公告称，公司第三届董事会第十四次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 8月14日晚间，海森药业发布公告称，公司第三届监事会第十三次会议审议通过了《关于 公司2025年半年度报告全文及摘要的议案》等多项议案。 ...

证券日报网讯 8月14日晚间，海森药业发布2025年半年度报告摘要称，公司2025年半年度实现营业收入 为242，085，860.34元，同比增长14.93%；实现归属于上市公司股东的净利润为60，794，153.31元， 同比增长4.74%。 （文章来源：证券日报） ...

Core Viewpoint - Haosen Pharmaceutical reported strong financial performance for the first half of 2025, achieving record revenue and profit levels since its listing, driven by robust market demand and effective production optimization [2][3]. Financial Performance - The company achieved operating revenue of 242 million yuan, a year-on-year increase of 14.93% [2]. - Net profit attributable to shareholders reached 60.79 million yuan, up 4.74% year-on-year [2]. - Deducting non-recurring gains and losses, the net profit was 59.25 million yuan, reflecting a growth of 4.82% [2]. Market Dynamics - Haosen Pharmaceutical experienced strong order volumes for its main products, indicating a favorable supply-demand balance [2]. - The company reported a significant increase in overseas sales, which rose by 53.04% year-on-year, highlighting successful international market expansion [2]. Research and Development - R&D investment amounted to 17.71 million yuan, representing 7.32% of operating revenue, with a year-on-year increase of 52.83% [2]. - The company is actively pursuing diverse channels for R&D成果转化, aiming to convert research outcomes into market value [2]. - As of the reporting period, there are 17 products under development, including APIs and intermediates targeting various therapeutic areas [2]. Strategic Initiatives - Haosen Pharmaceutical signed an investment cooperation agreement with the Dongyang Economic Development Zone to establish a new production facility [3]. - The new facility will include a project for the annual production of 300 tons of A-40 (Atorvastatin Calcium) [3]. - The company's R&D center and office building are expected to be operational by the end of September 2025, enhancing its R&D capabilities and production capacity [3].

（文章来源：证券日报） 证券日报网讯 8月14日晚间，海森药业发布公告称，董事会同意聘任吴洋宽先生为公司副总经理。 ...

海森药业（SZ 001367，收盘价：25.86元）8月14日晚间发布半年度业绩报告称，2025年上半年营业收 入约2.42亿元，同比增加14.93%；归属于上市公司股东的净利润约6079万元，同比增加4.74%；基本每 股收益0.41元，同比增加5.13%。 （文章来源：每日经济新闻） ...